Optimizing the structure of TTR Ligands for Half-life Extension (TLHE) of Peptides

Lead Author Affiliation

Pharmaceutics and Medicinal Chemistry

Introduction/Abstract

The tremendous therapeutic potential of peptides has not been fulfilled and potential peptide therapies that have failed far outnumber the successes so far. A major challenge impeding the more widespread use of peptides as therapeutics is their poor pharmacokinetic profile, due to short in vivo half-life resulting from inactivation by serum proteases and rapid elimination by kidneys.

Location

DUC Ballroom A&B

Format

Poster Presentation

This document is currently not available here.

Share

COinS
 
Apr 30th, 1:00 PM Apr 30th, 3:30 PM

Optimizing the structure of TTR Ligands for Half-life Extension (TLHE) of Peptides

DUC Ballroom A&B

The tremendous therapeutic potential of peptides has not been fulfilled and potential peptide therapies that have failed far outnumber the successes so far. A major challenge impeding the more widespread use of peptides as therapeutics is their poor pharmacokinetic profile, due to short in vivo half-life resulting from inactivation by serum proteases and rapid elimination by kidneys.